Ovid Therapeutics
OVID
38 hedge funds and large institutions have $26.6M invested in Ovid Therapeutics in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 9 closing their positions.
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
42% more capital invested
Capital invested by funds: $18.7M → $26.6M (+$7.86M)
9% more funds holding
Funds holding: 35 → 38 (+3)
4.95% less ownership
Funds ownership: 26.16% → 21.21% (-5%)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$468K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$341K |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$295K |
| 4 |
Renaissance Technologies
New York
|
+$262K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$2.87M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$1.4M |
| 3 |
Millennium Management
New York
|
-$561K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$277K |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$158K |
OVID Hedge Fund Activity: Q3 2019 in Review
38 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2019, worth a combined $26.6M — up 42% from $18.7M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new OVID positions and 9 closed out — a net gain of 4 holders — while 7 added to existing stakes and 12 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $468K. The largest seller was BVF Inc, cutting an estimated $2.87M.
- 38 institutional investors held Ovid Therapeutics (OVID) as of Q3 2019, up from 35 in Q2 2019.
- Funds reported $26.6M of Ovid Therapeutics stock for Q3 2019, up 42% quarter-over-quarter.
- 13 funds opened new Ovid Therapeutics positions in Q3 2019 and 9 closed out, a net change of +4 holders.
- The largest Ovid Therapeutics buyer in Q3 2019 was EAM Investors, an estimated $468K added.
- The largest Ovid Therapeutics seller in Q3 2019 was BVF Inc, an estimated $2.87M sold.
Based on aggregated 13F filings for Q3 2019.